Sökning: onr:"swepub:oai:DiVA.org:oru-112412" >
ADHD Pharmacotherap...
-
Li, LinKarolinska Institutet
(författare)
ADHD Pharmacotherapy and Mortality in Individuals With ADHD
- Artikel/kapitelEngelska2024
Förlag, utgivningsår, omfång ...
-
American Medical Association (AMA),2024
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:oru-112412
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-112412URI
-
https://doi.org/10.1001/jama.2024.0851DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:238470385URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is associated with increased risks of adverse health outcomes including premature death, but it is unclear whether ADHD pharmacotherapy influences the mortality risk. OBJECTIVE: To investigate whether initiation of ADHD pharmacotherapy was associated with reduced mortality risk in individuals with ADHD. DESIGN,SETTING, AND PARTICIPANTS: In an observational nationwide cohort study in Sweden applying the target trial emulation framework, we identified individuals aged 6 through 64 years with an incident diagnosis of ADHD from 2007 through 2018 and no ADHD medication dispensation prior to diagnosis. Follow-up started from ADHD diagnosis until death, emigration, 2 years after ADHD diagnosis, or December 31, 2020, whichever came first.EXPOSURES: ADHD medication initiation was defined as dispensing of medication within 3 months of diagnosis. MAIN OUTCOMES AND MEASURES: We assessed all-cause mortality within 2 years of ADHD diagnosis, as well as natural-cause (eg, physical conditions) and unnatural-cause mortality (eg, unintentional injuries, suicide, and accidental poisonings).RESULTS: Of 148 578 individuals with ADHD (61 356 females [41.3%]), 84 204 (56.7%) initiated ADHD medication. The median age at diagnosis was 17.4 years (IQR, 11.6-29.1 years). The 2-year mortality risk was lower in the initiation treatment strategy group (39.1 per 10 000 individuals) than in the noninitiation treatment strategy group (48.1 per 10 000 individuals), with a risk difference of -8.9 per 10 000 individuals (95% CI, -17.3 to -0.6). ADHD medication initiation was associated with significantly lower rate of all-cause mortality (hazard ratio [HR], 0.79; 95% CI, 0.70 to 0.88) and unnatural-cause mortality (2-year mortality risk, 25.9 per 10 000 individuals vs 33.3 per 10 000 individuals; risk difference, -7.4 per 10 000 individuals; 95% CI, -14.2 to -0.5; HR, 0.75; 95% CI, 0.66 to 0.86), but not natural-cause mortality (2-year mortality risk, 13.1 per 10 000 individuals vs 14.7 per 10 000 individuals; risk difference, -1.6 per 10 000 individuals; 95% CI, -6.4 to 3.2; HR, 0.86; 95% CI, 0.71 to 1.05).CONCLUSIONS AND RELEVANCE: Among individuals diagnosed with ADHD, medication initiation was associated with significantly lower all-cause mortality, particularly for death due to unnatural causes.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Zhu, NanboKarolinska Institutet
(författare)
-
Zhang, LeDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
(författare)
-
Kuja-Halkola, RalfKarolinska Institutet
(författare)
-
D'Onofrio, Brian M.Karolinska Institutet
(författare)
-
Brikell, IsabellKarolinska Institutet
(författare)
-
Lichtenstein, PaulKarolinska Institutet
(författare)
-
Cortese, SamueleCentre for Innovation in Mental Health-School of Psychology, Faculty of Environmental and Life Sciences, and Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, United Kingdom; New York University Child Study Center, Hassenfeld Children's Hospital at NYU Langone, New York; Solent NHS Trust, Southampton, United Kingdom; Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Studies of Bari Aldo Moro, Bari, Italy
(författare)
-
Larsson, Henrik,1975-Örebro universitet,Institutionen för medicinska vetenskaper(Swepub:oru)hiln
(författare)
-
Chang, ZhengKarolinska Institutet
(författare)
-
Karolinska InstitutetDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of the American Medical Association (JAMA): American Medical Association (AMA)331:10, s. 850-8600098-74841538-3598
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Li, Lin
-
Zhu, Nanbo
-
Zhang, Le
-
Kuja-Halkola, Ra ...
-
D'Onofrio, Brian ...
-
Brikell, Isabell
-
visa fler...
-
Lichtenstein, Pa ...
-
Cortese, Samuele
-
Larsson, Henrik, ...
-
Chang, Zheng
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Psykiatri
- Artiklar i publikationen
-
Journal of the A ...
- Av lärosätet
-
Örebro universitet
-
Karolinska Institutet